Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from ICER

Wegovy And Zepbound Cost Effective But They Could Break Drug Budgets

The Institute for Clinical and Economic Review (ICER) on Tuesday released a Draft Evidence Report assessing the comparative clinical effectiveness and value of Novo Nordisk A/S’ (NYSE:NVO) semaglutide (Wegovy) and Eli Lilly and Co.’s (NYSE:LLY) tirzepatide (Zepbound) for obesity management.

Is a new painkiller too good to be true?

Is a new painkiller too good to be true?

Meet suzetrigine, a non-opioid that promises to avoid addiction risk. But some experts say it can't replace opioids

FDA Advisers Overwhelmingly Oppose Approval of MDMA As a Psychotherapeutic Catalyst

The panel's recommendation, based on several concerns about two clinical trials, is a serious setback for a promising PTSD treatment.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

As the FDA evaluates ecstasy treatment for PTSD, questions mount about the evidence

Clinical trials of MDMA have been promising, but concerns have emerged about the quality of the research. A June hearing scheduled by the Food and Drug Administration is likely to address them.

Ozempic isn't alone. A whole class of 'revolutionary' weight-loss drugs is on the market—but only for the wealthy

“We're experiencing something here that is very, very different, very exciting from a healthcare perspective, and very expensive,” says Aon's Michael Manolakis.

Indian scientist gets Bailey K Ashford Medal for work in tropical medicine

The world's largest scientific organization in tropical medicine, the American Society of Tropical Medicine and Hygiene, has awarded the prestigious 2022 Bailey K Ashford Medal. Read more on Dynamite News:

New generation of weight loss medications offer promise — but at a price

Excitement is building about a new generation of drugs that tout the ability to help adults with excess weight shed more pounds than older drugs on the market.

Tribune News Service

inkl

Read news from The Economist, FT, and more,
with one subscription

Commentary: Mark Cuban won’t fix our drug pricing problem

Mark Cuban, the billionaire “Shark Tank” celebrity and Dallas Mavericks owner, is getting attention again — this time for his Mark Cuban Cost Plus Drug Co., which seeks to reduce prescription drug prices for Americans. A new study finds that Medicare could have saved $3.6 billion in 2020 if it…

Los Angeles Times

Here's How Citi Views Amylyx Pharma

Here's How Citi Views Amylyx Pharma

Citi Research has raised the price target on Amylyx Pharmaceuticals Inc's (NASDAQ:AMLX) to $33 from $32, with a Buy rating. It says the small market opportunity for the newly approved amyotrophic lateral sclerosis (ALS) drug in Canada (~$100 million peak) bodes well for ongoing FDA review. Availability in Canada and using ALSFRS-R data as the primary basis…

Lilly's Tirzepatide Shows Up To 22.5% Weight Loss In New Phase 3 Readout

Lilly's Tirzepatide Shows Up To 22.5% Weight Loss In New Phase 3 Readout

Eli Lilly And Co (NYSE:LLY) reported topline results from SURMOUNT-1 Phase 3 trial evaluating Tirzepatide (5 mg, 10 mg, 15 mg) in obese patients with at least one comorbidity who do not have diabetes. Data exhibited that tirzepatide reduced patients' weights by an average of 16%, 21.4%, and 22.5% at the respective doses,…

ICER's Report Suggests Benefits Of Eli Lilly's Tirzepatide Not Better Than Other Diabetes Drugs

ICER's Report Suggests Benefits Of Eli Lilly's Tirzepatide Not Better Than Other Diabetes Drugs

Institute for Clinical and Economic Review (ICER) casts doubts on Eli Lilly And Co’s (NYSE: LLY) tirzepatide, a type II diabetes candidate, about its usefulness to patients compared to the rivals.

People

Jennifer Mitchell

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Dallas Mavericks

the Food and Drug Administration

Eli Lilly And Co

University of Illinois Chicago

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Prescription Drug

Places

323,047 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play